Key Highlights
- Collaboration and license Revenue for the third quarter of 2026 was USD 10.0 million, down from USD 19.1 million a year earlier, because less revenue was recognized under the AbbVie and Gilead agreements.
- The net loss narrowed to USD 5.9 million, or USD 0.30 per share, from USD 16.3 million, or USD 1.58, helped by a USD 4.8 million gain on Warrant liabilities versus a USD 15.4 million loss.
- Loss from operations widened to USD 11.7 million from USD 1.9 million, with operating expenses of USD 21.7 million, including Research and Development of USD 14.8 million, up 3.4% from USD 14.3 million.
- Cash and cash equivalents were USD 122.2 million at September 30, 2026, which management expects to fund operations into the first quarter of 2028, excluding potential warrant proceeds and milestones.
Collaboration Revenue Drops Sharply but the Net Loss Shrinks
Xilio Therapeutics (NASDAQ:XLO) filed its Quarterly Report on November 10, 2026, for the quarter ended September 30, 2026. The clinical-stage company develops masked immuno-oncology therapies designed to switch on inside tumors. All revenue comes from collaboration and license agreements with AbbVie and Gilead, and it fell 47.6% (calculated) to USD 9.98 million. The Bottom Line improved for a different reason. A USD 4.8 million non-cash gain on the Fair Value of common stock warrant liabilities replaced a USD 15.4 million loss a year earlier, so the USD 5.9 million net loss was flattered by an accounting item rather than by operations.
Nine-Month Revenue Is Up Even as the Third Quarter Slips
Over nine months, revenue rose to USD 41.3 million from USD 30.1 million, as higher AbbVie revenue outweighed a decline from Gilead. Research and development expenses were USD 49.2 million versus USD 37.9 million, and the nine-month net loss narrowed to USD 21.9 million, or USD 1.18 per share, from USD 45.4 million, or USD 6.03. Per-share figures reflect a 1-for-14 Reverse Stock Split effective March 13, 2026 and a larger share count, with weighted average shares of 19.7 million versus 10.3 million. Accumulated Deficit was USD 440.6 million. Xilio Therapeutics (NASDAQ:XLO) has no product revenue and does not expect any for several years.
Cash Runway, Possible Milestones and Pipeline Dates
Management expects cash of USD 122.2 million to last into the first quarter of 2028. That excludes up to USD 36.2 million in gross proceeds if all Series C warrants are exercised in the fourth quarter of 2026 at the current price, and up to USD 31.0 million in near-term AbbVie milestones and option extension fees through the first half of 2027. The lead program, XTX501, a PD-1 and masked IL-2 bispecific, has begun patient dosing, with initial lung cancer data planned for the fourth quarter of 2027. Investigational new drug filings for XTX602 and XTX701 are also planned for that quarter, and an option data package for efarindodekin alfa is due to Gilead in the first half of 2027.
Where Things Stand
Revenue fell because less collaboration revenue was recognized under the AbbVie and Gilead agreements, and the filing gives no further breakdown for the quarter. Xilio Therapeutics (NASDAQ:XLO) still narrowed its net loss, but mainly through a USD 4.8 million warrant fair value gain, since the operating loss widened to USD 11.7 million. The Balance Sheet is the strength, with USD 122.2 million of cash and a runway into early 2028. Next markers are the fourth-quarter Series C warrant exercises, AbbVie milestone decisions, the Gilead option package and XTX501 data in late 2027.




_11_13_2026_20_27_09_053340.jpg)

Please wait processing your request...